[Weekly paclitaxel infusion in patients with recurrent ovarian cancer--a pilot study].

This preliminary study was performed to evaluate the safety and efficacy of weekly paclitaxel administration by 1-hour infusion. A total of 7 patients with recurrent ovarian cancer were treated with weekly paclitaxel (TXL). TXL was given at a dose of 70 mg/m2 in 1-hour infusions every week for at least 20 consecutive weeks unless lesions became progressive.

[A case of extraovarian primary peritoneal carcinoma successfully treated with weekly paclitaxel].

We report the use of paclitaxel in the successful treatment of a 74-year-old patient with extraovarian primary peritoneal carcinoma and acute renal failure caused by intraperitoneal cisplatin. The histological diagnosis was papillary serous adenocarcinoma. Paclitaxel was given intravenously at 70 mg/m2 in a 1-hour infusion weekly for 6 consecutive weeks followed by 2-weeks rest (one cycle).